Last reviewed · How we verify
BL0175
At a glance
| Generic name | BL0175 |
|---|---|
| Sponsor | Shanghai Best-Link Bioscience, LLC |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study of Single Dose of BL0175 in Postmenopausal Women (PHASE1)
- A Study of BL0175 Injection in Postmenopausal Female Adults With HR-positive, Locally Advanced or Metastatic Cancer (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BL0175 CI brief — competitive landscape report
- BL0175 updates RSS · CI watch RSS
- Shanghai Best-Link Bioscience, LLC portfolio CI